Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of “Hold” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given a consensus rating of “Hold” by the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $30.70.

Several equities analysts recently commented on the stock. Citigroup increased their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, June 8th. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a research note on Tuesday, May 12th. Truist Financial lifted their target price on shares of Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 price target on shares of Hims & Hers Health in a research report on Tuesday, May 5th.

Insider Activity at Hims & Hers Health

In other news, insider Irene Becklund sold 4,490 shares of Hims & Hers Health stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $141,435.00. Following the completion of the sale, the insider owned 6,790 shares in the company, valued at $213,885. The trade was a 39.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 7,163 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87. Following the transaction, the chief financial officer owned 284,321 shares in the company, valued at $10,374,873.29. The trade was a 2.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 167,161 shares of company stock worth $5,041,152. Corporate insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health in the first quarter valued at $30,000. EverSource Wealth Advisors LLC grew its holdings in shares of Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after buying an additional 687 shares during the last quarter. Amundi grew its holdings in shares of Hims & Hers Health by 5.3% during the second quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after buying an additional 522 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in shares of Hims & Hers Health by 9.5% during the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after buying an additional 29,471 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Up 0.0%

Shares of NYSE HIMS opened at $34.40 on Tuesday. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The company has a market cap of $7.96 billion, a price-to-earnings ratio of -382.19, a PEG ratio of 96.75 and a beta of 2.35. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The stock has a 50-day moving average price of $29.51 and a two-hundred day moving average price of $26.33.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company posted $0.20 EPS. As a group, analysts forecast that Hims & Hers Health will post 0.03 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.